

PUBLISHER CORRECTION

Open Access



Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia

Anja C. Rathgeber^{1,2,3}, Stacey M. Fernandes⁴, Adi Nagler⁴, Shuqiang Li^{5,10}, David M. Dorfman⁶, Lars Bullinger^{7,8,9}, Matthew S. Davids⁴, Jennifer R. Brown⁴, Kenneth J. Livak⁵, Leif S. Ludwig^{1,2}, Catherine J. Wu^{4,10,11} and Livius Penter^{4,7,8,12*}

The original article can be found online at <https://doi.org/10.1186/s13059-026-04072-4>.

*Correspondence:
livius.penter@charite.de

⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Full list of author information is available at the end of the article

Publisher Correction: *Genome Biol* 27, 175 (2026)

<https://doi.org/10.1186/s13059-026-04072-4>

Following publication of the original article [1], a typesetting error was noticed, whereby the full “competing interest” declaration was not published. The correct declaration is:

C.J.W. is an equity holder of BioNTech, Inc, receives research funding from Pharmacyclics, and is a SAB member of Repertoire, Nature’s Toolbox, Aethon Therapeutics, and Adventris.

K.J.L. reports equity in Standard BioTools Inc. and serves on the scientific advisory board for MBQ Pharma Inc.

L.B. received honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Otsuka, Pfizer, Roche, and Sanofi; research funding from Bayer, Jazz Pharmaceuticals.

M.S.D. has received institutional research funding from AstraZeneca and Ascentage Pharma.; and received personal consulting income from AbbVie, Ascentage Pharma, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Eli Lilly, Genentech, Genmab, Janssen, Merck, Nuvalent, and Schrödinger, and receives royalties from UpToDate.

J.R.B. has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Alloplex Biotherapeutics, BeiGene, Bristol-Myers Squibb, EcoR1, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc, Kite Pharma, Loxo/Lilly, Magnet Biomedicine, Merck, Numab Therapeutics, Nurix Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, Nagoon Therapeutics, and TG Therapeutics; serves on the Data Safety Monitoring Board for Grifols Therapeutics; and receives royalties from UpToDate.



© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

The Broad Institute has filed for patents relating to the use of technologies described in this paper, where L.S.L. is named an inventor (US patent applications 17/251,451 and 17/928,696).

L.S.L. is a Guest Editor for *Genome Biology*'s "Leveraging mitochondria to understand health and disease" collection but was not involved in the editorial process of this manuscript.

All other authors do not have any relevant conflict of interest.

The original article [1] has been updated.

Author details

¹Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany. ²Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany. ³Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin, Berlin, Germany. ⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ⁵Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA. ⁶Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁷Department of Hematology, Oncology, and Cancer Immunology, Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin 13353, Germany. ⁸German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁹National Center for Tumor Diseases (NCT), partner site Berlin, Berlin, Germany. ¹⁰Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, USA. ¹¹Harvard Medical School, Boston, USA. ¹²Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Berlin, Germany.

Published online: 02 June 2026

Reference

1. Rathgeber AC, Fernandes SM, Nagler A, et al. Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia. *Genome Biol.* 2026;27:175. <https://doi.org/10.1186/s13059-026-04072-4>.